Neuralink has paused its attempts to trademark “Telepathy” and “Telekinesis” following intervention from the United States Patent and Trademark Office (USPTO). Letters from the USPTO in August notified the company that its application cannot proceed because another individual, Wesley Berry, filed for those same marks first—Telepathy in May 2023 and Telekinesis in August 2024
Berry, co-founder of the startup Prophetic, has not commercialized products under these names. His trademark applications describe EEG-based software intended to decode brain signals for device control—similar in scope to Neuralink’s intended use. In addition, Neuralink’s applicant response addressed a separate mark held by Telepathy Labs but notably did not comment on Berry’s filings
The USPTO’s pause isn’t a final rejection yet—it stems from what is known as “intent-to-use” filings that allow reservation of trademark rights before commercialization. Since Berry’s filings predate Neuralink’s, he currently holds the stronger claim. Should Berry register the trademarks and then restrict use, Neuralink may need to negotiate—through purchase, consent agreement, or, if necessary, defend its use legally
Meanwhile, Neuralink continues advancing its clinical trials. Just this past week (end of August to early September 2025), surgical procedures testing its brain-computer interface for spinal injury patients took place at Toronto Western Hospital—demonstrating that product development remains ongoing despite the trademark roadblock NewsBytes.
Why This Matters
- Branding Strategy Hits a Snag
Without securing rights to “Telepathy” and “Telekinesis,” Neuralink may need to rework how it positions these products—names integral to buzz and recognition in emerging neurotech. - First-to-File Advantage Prevails
Berry’s earlier filings highlight the importance of timing in trademark law—even for companies with much greater visibility and backing. - Commercial and Legal Options Ahead
Neuralink could still pursue negotiation or licensing agreements if Berry secures full registration; alternatively, litigation is a last-resort path. - Product Development Continues
Neuralink’s clinical momentum remains strong: recent surgeries in Canada highlight its commitment to advancing its BCI tech regardless of naming disputes.
